Immunovant (IMVT)
(Delayed Data from NSDQ)
$27.87 USD
-1.00 (-3.46%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $27.88 +0.01 (0.04%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMVT 27.87 -1.00(-3.46%)
Will IMVT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMVT
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound?
IMVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
Other News for IMVT
First Week of IMVT August 16th Options Trading
Buy Rating Affirmed for Immunovant Amidst Market Expansion and Promising Clinical Trials
Argenx: Strong Setup For Outperformance In 2025
Immunovant: Overvalued Amidst M&A Speculation
Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive